Chardan Research initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) on Wednesday, citing the potential of its epilepsy franchise. Analyst Rudy Li writes, “Epilepsy remains one of our ...
Praxis Precision Medicines, Inc. announced significant progress in its clinical pipeline, projecting six major study readouts across four programs in the next 12 months. The company plans to initiate ...
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures ...
“It’s an incredibly exciting time for Praxis and our epilepsy portfolio, as we share updates from first-in-patient and Phase 2 studies for elsunersen (PRAX-222), PRAX-562 and PRAX-628,” said Marcio ...
Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) soared 27% on Monday after the company released encouraging top-line results from its Phase 2 RADIANT trial, which evaluated vormatrigine in ...
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) ...
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced Monday several clinical and regulatory developments for its epilepsy drug candidates, according to a statement based on a recent SEC filing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback